Separation, identification, and characterization of degradation products of erlotinib hydrochloride under ICH-recommended stress conditions by LC, LC-MS/TOF

Journal of Liquid Chromatography and Related Technologies

Volumn 38, Issue 5, 2015, Pages 629-639

  Mahajan, Anand A ^a   Miniyar, Pankaj B ^a   Patil, Amol S ^a   Waghmare, Rohan U ^a   Patil, Jayawant J ^b   Mohanraj, Krishnapriya ^b   Tiwari, Ravi N ^c  

^a Sinhgad Institute of Pharmacy   (India)

^b BOMBAY COLLEGE OF PHARMACY   (India)

^c SVKM s Narsee Monjee Institute of Management Studies   (India)

Author keywords

characterization; degradation pathway; erlotinib hydrochloride; LC MS TOF; stability indicating method; stress study

Indexed keywords

DEGRADATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THERMAL STRESS;

DEGRADATION PATHWAYS; ERLOTINIB; LC-MS/TOF; STABILITY INDICATING METHOD; STRESS STUDIES;

SEPARATION;

6 (2 HYDROXYETHOXY) 7 (2 METHOXYETHOXY)QUINAZOLIN 4 AMINE; 6,7 BIS(2 METHOXYETHOXY)QUINAZOLIN 4 AMINE; ACID; BASE; DRUG METABOLITE; ERLOTINIB; N (3 ETHYNYLPHENYL) 6,7 BIS(2 METHOXYETHOXY) 2 OXYQUINAZOLIN 4 AMINE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL EQUIPMENT; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG IDENTIFICATION; DRUG STABILITY; DRUG STRUCTURE; ELUTION; FRAGMENTATION REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATION; PHOTOLYSIS; SEPARATION TECHNIQUE; TEMPERATURE STRESS; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 84921276355     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826076.2014.936610     Document Type: Article

References (40)

1. Dowell, J.; Minna, J. D.; Kirkpatrick, P. Fresh from the Pipeline Erlotinib Hydrochloride. Nature Reviews Drug Discovery 2005, 4, 13-14.
2. Padmalatha, M.; Kulsum, S.; Rahul, C.; Reddy, D. T.; Vidyasagar, G. Spectrophotometric Methods for the Determination of Erlotinib in Pure and Pharmaceutical Dosage Forms. Int. J. Pharm. Res. Dev. 2011, 3 (6), 103-109.
3. Padmalatha, H.; Vidyasagar, G. Development and Validation of UV Spectrophotometric Method for the Determination of Erlotinib in Tablet Formulation. Imperial J. Med. Org. Chem. 2011, 1 (1), 26-30.
4. Mandal, B.; Balabathula, P.; Mittal, N.; Wood, G. C.; Bhattacharjee, H. Development and Validation of a Spectro-fluorimetric Method for the Determination of Erlotinib in Spiked Human Plasma. J. Fluoresc. 2012, 22, 1425-1429.
5. Rajesh, V.; Anupama, B.; Jagathi, V.; Varaprasad, K. High Performance Thin Layer Chromatographic Method for Estimation of Erlotinib Hydrochloride as Bulk Drug. Int. J. Biol. Med. Res. 2011, 2 (1), 433-435.
6. Ding, X.; Zhang, C.; Xu, Z.; Zhang, Q.; Wu, H.; Ma, Z. W. J. Determination of Erlotinib in Rabbit Plasma by Liquid Chromato-graphy Mass Spectrometry. Lat. Am. J. Pharm. 2012, 31 (4), 501-506.
7. Pan, J.; Jiang, X.; Yu-Luan, C. Automatic Supported Liquid Extraction (SLE) Coupled with HILIC-MS/MS: An Application to Method Development and Validation of Erlotinib in Human Plasma. Pharmaceutics 2010, 2 (2), 105-118.
8. Lepper, E. R.; Swain, S. M.; Tan, A. R.; Figg, W. D.; Sparreboom, A. Liquid-Chromatographic Determination ofErlotinib (OSI-774), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 796 (1), 181-188.
9. Zhao, M.; He, P.; Rudek, M. A.; Hidalgo, M.; Baker, S. D. Specific Method for Determination of OSI-774 and Its Metabolite OSI-420 in Human Plasma by Using Chromatography-Tandem Mass Spectrometry. J. Chromatogr. B 2003, 793 (2), 413-420.
10. Honeywell, R.; Yarzadah, K.; Giovannetti, E.; Losekoot, N.; Smit, E. F.; Walraven, M.; Lind, J. S. W.; Tibaldi, C.; Verheul, H. M.; Peters, G. J. Simple and Selective Method for the Determination of Various Tyrosine Kinase Inhibitors Used in the Clinical Setting by Liquid Chromatography Tandem Mass Spectrometry. J. Chromatogr. B 2010, 878 (15-16), 1059-1068.
11. Signor, L.; Varsesio, E.; Staack, R. F.; Starke, V.; Richter, W. F.; Hopfgartner, G. Analysis of Erlotinib and Its Metabolites in Rat Tissue Sections by MALDI Quadrupole Time-of-Flight Mass Spectrometry. J. Mass. Spect. 2007, 42 (7), 900-909.
12. Karunakara, C.; Udupi, A.; Chandregowda, V.; Reddy, V. C. G. Separation and Determination of Process-Related Impurities of Erlotinib Using Reverse-Phase HPLC with a Photo-Diode Detector. Anal. Sci. 2012, 28, 305-308.
13. Pujeri, S. S.; Khader, A. M. A.; Seetharamappa, J. Validated Stability-Indicating Chromatographic Method for the Assay of Erlotinib Active Pharmaceutical Ingredient. Anal. Lett. 2009, 42, 1855-1867.
14. Bouchet, S.; Chauzit, E.; Ducint, D.; Castaing, N.; Canal-Raffin, M.; Moore, N. Simultaneous Determination of Nine Tyrosine Kinase Inhibitors by 96-Well Solid-Phase Extraction and Ultra Performance LC/MS-MS. Clin. Chim. Acta 2011, 412 (11-12), 1060-1067.
15. Chakravarthy, V. K.; Shankar, D. G. Development and Validation of RP-HPLC Method for Estimation of Erlotinib in Bulk and Its Pharmaceutical Formulation. Rasayan J. Chem. 2011, 4 (2), 393-399.
16. Conaway, M. C. P.; Bui, H.; Beachy, S.; Pitoniak, R.; Hylander, B.; Wang, P.; Marlar, K.; Repasky, E.; Kazim, L. Determining Distribution of Erlotinib in Pancreatic Tumors by MALDI Using an LTQ Linear Ion Trap, LCGC North Am. The Application Notebook - June 2008 Advertising Supplement 58, 2008.
17. Couchman, L.; Birch, M.; Ireland, R.; Corrigan, A.; Wickramasinghe, S.; Josephs, D.; Spicer, J.; Flanagan, R. J. An Automated Method for the Measurement of a Range of Tyrosine Kinase Inhibitors in Human Plasma or Serum Using Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry. Anal. Bioanal. Chem. 2012, 403, 1685-1695.
18. Dziadosz, M.; Lessig, R.; Bartels, H. HPLC-DAD Protein Kinase Inhibitor Analysis in Human Serum. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2012, 893-894, 77-81.
19. Faivre, L.; Gomo, C., Mir, O.; Taieb, F.; Schoemann-Thomas, A.; Ropert, S.; Vidal, M.; Dusser, D.; Dauphin, A.; Goldwasser, F., Blanchet, B. A Simple HPLC-UV Method for the Simultaneous Quantification of Gefitinib and Erlotinib in Human Plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879 (23), 2345-2350.
20. Gomez-Canela, C.; Cortes-Francisco, N.; Ventura, F.; Caixach, J.; Lacorte, S. Liquid Chromatography Coupled to Tandem Mass Spectrometry and High Resolution Mass Spectrometry as Analytical Tools to Characterize Multiclass Cytostatic. J. Chromatogr. A 2013, 1276,78-94.
21. Konda, R. K.; Babu, K. S.; Nagabhushanam, C. H. A validated LC Method for the Estimation of Erlotinib in Bulk and Tablet Dosage Form. Int. J. Pharm. Biomed. Res. 2013, 4 (1), 1-4.
22. Lankheet, N. A.; Hilebrand, M. J.; Rosing, H.; Schellens, J. H.; Beijnen, J. H.; Huitema, A. D. Method Development and Validation for the Quantification of Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Nilotinib, Sorafenib and Sunitinib in Human Plasma by Liquid Chromatography Coupled with Mass Spectro-metry. Biomed. Chromatogr. 2013, 27 (4), 466-476.
23. Lankheet, N. A.; Schaake, E. E.; Rosing, H.; Burgers, J. A.; Schellens, J. H.; Beijnen, J. H.; Huitema, A. D. Quantitative Estimation of Erlotinib and O-Desmethyl Erlotinib in Human EDTA Plasma and Lung Tumor Tissue. Bioanalysis 2012, 4 (21), 2563-2577.
24. Li, H-Q.; Chen, Y.; Li, Z-Q.; Deng, C-H.; Li, L.; Bi, S.-S.; Li, M.-Y.; Zhou, T.-Y.; Lu, W. A High Performance Liquid Chroma-tography Method for the Quantitative Determination of Erlotinib in the Plasma of Tumor Bearing BALB/C Nude Mice and Its Application in a Pharmacokinetic Study. J. Chin. Pharm. Sci. 2011, 20 (3), 245-252.
25. Negreira, N.; Lopez, de Alda M.; Barcelo, D. Online Solid Phase Extraction-Liquid Chromatography Tandem Mass Spectrometry for the Determination of 17 Cytostatics and Metabolites in Waste, Surface and Ground Water Samples. J. Chromatogr. A 2013, 1280, 64-74.
26. Padmalatha, M.; Prakash, K. V.; Kusum, S., Kumar1, R. V.; Wilson1, K.; Vivekananda1, V. Development and Validation ofHigh Performance Liquid Chromatographic Method for the Determination of Erlotinib. J. Pharm. Res. 2011, 4 (3), 637-638.
27. Reddy, G. N. K.; Prasad, V. V. S. R.; Maharana, P. K. Development and Validation of a Stability Indicating UPLC Method for Determination of Erlotinib in Pharmaceutical Formulations. Pharma. Chem. 2012, 4 (6), 2288-2297.
28. Saravanan, V. S.; Rao, B. M. Analytical Method Development and Validation for the Determination of Erlotinib Hydrochloride Bulk and in Pharmaceutical Dosage Form. J. Drug Delivery. Ther. 2013, 3 (1), 50-54.
29. Signor, L.; Varesio, E.; Staack, R.; Starke, D.; Richter, W.; Hopfgartner, G. Analysis of Erlotinib and Its Metabolites in Rat Tissue Sections by MALDI Quadrupole Time-of-Flight Mass Spectrometry. J. Mass Spectrom. 2007, 42 (7), 900-909.
30. Streit, F.; Binder, L.; Hafke, A.; Brandhorst, G.; Braulke, F.; Haase, D.; Armbrust, T.; Cameron, S.; Ramadori, G.; Oellerich, M.; Walson, P. Use of Total and Unbound Imatinib and Metabolite LC-MS/MS Assay to Understand Individual Responses in CML and GIST Patients. Ther. Drug Monit. 2011, 33 (5), 632-643.
31. Thappali, S. R. S.; Varanasi, K.; Veeraraghavan, S.; Arla, R.; Chennupati, S.; Rajamanickam, M.; Vakkalanka, S.; Khagga, M. Simultaneous Determination of Celecoxib, Erlotinib, and Its Metabolite Desmethyl Erlotinib (OSI-420) in Rat Plasma by Liquid Chromatography/Tandem Mass Spectrometry with Positive/ Negative Ion-Switching Electrospray Ionisation. Sci. Pharm. 2012, 80 (3), 633-646.
32. Zhang, W.; Siu, L. L.; Moore, M. J.; Chen, E. X. Simultaneous Determination of OSI-774 and Its major Metabolite OSI-420 in Human Plasma by Using HPLC with UV Detection. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2005, 814 (1), 143-147.
33. Zhen, Y.; Thomas-Schoemann, A.; Sakji, L.; Boudou-Rouquette, P.; Dupin, N.; Mortier, L.; Vidal, M.; Goldwasser, F.; Blanchet, B. An HPLC-UV Method for the Simultaneous Quantification of Vemurafenib and Erlotinib in Plasma from Cancer Patients. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 928, 93-97.
34. Andriamanana, I.; Gana, I.; Duretz, B.; Hulin, A. Simultaneous Analysis of Anticancer Agents Bortezomib, Imatanib, Nilotinib, Dasatinib, Erlotinib, Lapatinib, Sorafenib, Sunitinib and Vandetanib in Human Plasma Using LC/MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 926, 83-91.
35. Masters, A. R.; Sweeney, C. J.; Jones, D. R. The Quantification of Erlotinib (OSI-774) and OSI-420 in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 848 (2), 379-383.
36. I.C.H. Stability Testing of New Drug Substances and Products Q1A(R2), in: International Conference on Harmonization, IFMPA, Geneva, 2003.
37. Mahajan, A. A.; Thaker, A. K.; Mohanraj, K. LC, LC-MS/MS Studies for the Identification and Characterization of Degradation Products of Hydrochlorothiazide and Establishment of Mechanistic Approach Towards Degradation. J. Braz. Chem. Soc. 2012, 23 (3), 445-452.
38. Mahajan, A. A.; Thaker, A. K.; Kale, S.; Mohanraj, K. 2012 LC, LC-MS/MS Studies for Identification and Characterization of Degradation Products of Lamotrigine and Establishment of Mechanistic Approach Towards Degradation. J. Liq. Chromatogr. Relat. Technol. 2012, 35 (16), 2255-2271.
39. Mahajan, A. A.; Thaker, A. K.; Kale, S.; Mohanraj, K. Study of Olopatadine Hydrochloride Under ICH Recommended Stress Conditions by LC-MS/TOF for Identification and Characterization of Degradation Products. J. Liq. Chromatogr. Relat. Technol. 2013, 36 (13), 1881-1898.
40. I.C.H. Validation of Analytical Procedures: Text and Methodology, Q2 (R1), International Conference on Harmonization IFPMA, Geneva, 2005.